lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
The Green Chemistry Institute (GCI) supports the "implementation of green chemistry and engineering throughout the global chemistry enterprise." The GCI organizes an annual conference, the Green Chemistry and Engineering Conference, provides research grants, administers awards, and provides information and support for green chemistry practices to educators, researchers, and industry. The GCI was founded in 1997 as an independent non-profit organization, by chemists Joe Breen and Dennis Hjeresen in cooperation with the Environmental Protection Agency. In 2001, the GCI became a part of the American Chemical Society.[1]
An2O3 + 3 H2O → 2 An(OH)3. These bases are poorly soluble in water and by their activity are close to the hydroxides of rare-earth metals. Np(OH)3 has not yet been synthesized, Pu(OH)3 has a blue color while Am(OH)3 is pink and Cm(OH)3 is colorless. Bk(OH)3 and Cf(OH)3 are also known, as are tetravalent hydroxides for Np, Pu and Am and pentavalent for Np and Am. The strongest base is of actinium. All compounds of actinium are colorless, except for black actinium sulfide (Ac2S3). Dioxides of tetravalent actinides crystallize in the cubic system, same as in calcium fluoride. Thorium reacting with oxygen exclusively forms the dioxide:
=== A10BB Sulfonylureas === A10BB01 Glibenclamide A10BB02 Chlorpropamide A10BB03 Tolbutamide A10BB04 Glibornuride A10BB05 Tolazamide A10BB06 Carbutamide A10BB07 Glipizide A10BB08 Gliquidone A10BB09 Gliclazide A10BB10 Metahexamide A10BB11 Glisoxepide A10BB12 Glimepiride A10BB31 Acetohexamide
They further argued, "In contrast, Moscow's timing suggests that Putin seeks to overthrow Saakashvili well ahead of our elections, and thus avoid beginning relations with the next president on an overtly confrontational note." They stated that Russia could attack Ukraine next. Former employee of the United States Department of Defense said that Russia wanted to change the government of Georgia and install a satrap. Member of the Parliament of the United Kingdom Bruce George said that he had no doubt that the South Ossetians were incited by Russia to launch the attack. Matthew Bryza, Deputy Assistant Secretary of State, said on 11 August that Russia had planned to invade Georgia beforehand and cited the deployment of the Russian railway troops to Abkhazia as proof. Senator John McCain said that NATO's refusal to offer membership to Georgia in April 2008 "might have been viewed as a green light by Russia for its attacks on Georgia." Ronald Asmus wrote on 12 August 2008 that the West was responsible for the propagation of Russia's role as peacekeeper. Asmus recalled that his European friend was advised by Russian official in late July 2008 to visit Georgia sooner because it could be late in September 2008. The New York Times reported on 12 August 2008 that Bush administration had been warning Georgia not to become involved in the conflict with Russia.
Sources: en.wikipedia.org
Immune-derived β-endorphin reduces pro-inflammatory cytokines such as IL-1 and IL-6 while increasing IL-10 and interferon-γ, contributing to systemic anti-inflammatory effects. β-Endorphin has approximately 18 to 33 times the analgesic potency of morphine, though its hormonal effect is species dependent. A comparative study found that patients with chronic neuropathic pain had significantly lower cerebrospinal-fluid β-endorphin concentrations than healthy controls.
Non-depolarizing drug Non-depolarizing neuromuscular blockers are indicated in general anesthesia to facilitate endotracheal intubation, and to aid in surgeries via muscle relaxation. They can be further separated into two classes, benzylisoquinolinium compounds, and aminosteroid compounds. Benzylisoquinolinium compounds, also known as benzylisoquinolines, have a structure of two quaternary ammonium groups linked by a chain of methyl groups. The methyl chain contains one or more chiral groups, leading to the existence of stereoisomers of benzylisoquinolinium drugs. Atracurirum, a bezylisoquinolinium drug, is commonly used in clinical settings. Atracurium: The recommended clinical dosage of atracurium for adults is to "dose to effect" approach to ensure muscle relaxation. The drug has a relatively intermediate duration of action when compared to other non-depolarizing agents. The drug has an onset of 2 to 3 minutes in adults and an expected peak effect at 3 to 5 minutes. Recovery is expected to begin within 20 to 35 minutes of the initial dose, but it may take up to 70 minutes to achieve 95% recovery. On the other hand, aminosteroid compounds have a structure based on androstane, with the addition of ACh-like groups. Vecuronium and pancuronium are the two most common aminosteroid compounds utilized in clinical settings. Vecuronium and pancuronium: The recommended dosage of vecuronium and pancuronium both vary depending on interpatient variability. These drugs aim to achieve adequate muscle relaxation for surgical procedures to prevent surgical trauma.
Representative Alexandria Ocasio-Cortez appeared on Bluesky a week after legacy blue checkmarks were removed. After beseeching Musk, actor Charlie Sheen regained his checkmark. Musician Sean Ono Lennon showed confusion towards celebrities who refused to pay for Twitter Blue. Ardent supporters of Musk have defended Twitter Blue, particularly noting its price point. Internet entrepreneur Jason Calacanis, entrepreneur David O. Sacks, and essayist Nassim Nicholas Taleb placed immense value into the subscription while tweeting about it, with Taleb calling those who pay for other products and services monthly but not Twitter Blue "domain dependent misers!" Right-wing Twitter user Catturd called critics of Twitter Blue "elitist snobs".
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.